$AKYA News
Last published 1y ago
- 1y agoQTRXAKYAKent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative ProposalPR NewswireKent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the...
- 1y agoONCYAKYAQTRXTCRX+1New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer BiotechsPR NewswireEquity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is...
- 1y agoAKYAAkoya Biosciences Reports First Quarter 2025 Financial ResultsGlobeNewswireMARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31,
- 1y agoAKYAQTRXKent Lake Issues Statement on Quanterix's Blatant Disregard for Will of ShareholdersBusiness WireIt is Deeply Disturbing, in Kent Lake's View, that the Company's Amended Agreement to Merge with Akoya Deprives Quanterix Shareholders of Ability to Vote on the Transaction Believes Quanterix's Maneuvers Further
- 1y agoAKYAQTRXQuanterix and Akoya Biosciences Announce Amended Merger AgreementBusiness WireQuanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and
- 1y agoAKYAAkoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics AtlasGlobeNewswireMARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and Enable Medicine, a real-world data company providing AI-ready patient, cellular and
- 1y agoAKYAAkoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025GlobeNewswireMARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, today announced the availability of a new assay designed to advance antibody-drug
- 1y agoAKYAAkoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in SingaporeGlobeNewswireThe STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study is a multi-institutional study led by STCC with the goal of identifying predictors of PD1 immunotherapy response in an Asian real-world setting, bringing
- 1y agoAKYAQTRXKent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix ShareholdersBusiness WireUrges Shareholders to Vote AGAINST Both Proposals Related to the Value-Destructive Merger with Akoya at the Upcoming Special Meeting Notes Deeply Unfair Merger is Effectively a Bailout for Akoya at the Expense of
- 1y agoAKYAQTRXTikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya BiosciencesBusiness WireTikvah Management LLC (together with its affiliates, "Tikvah" or "we"), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued a
- 1y agoAKYAQTRXKent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled AkoyaBusiness WireDisturbed that Quanterix Is Apparently Moving Forward with One of the Most Shareholder Unfriendly Aspects of Merger Agreement with Akoya Encourages Shareholders to Vote AGAINST Both Proposals Related to Approval of the
- 1y agoAKYAAkoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer InequitiesGlobeNewswireAkoya's technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative The unprecedented scale of the initiative
- 1y agoAKYAQTRXTikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya BiosciencesBusiness WireTikvah Management LLC (together with its affiliates, "Tikvah" or "we"), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (NASDAQ:QTRX) ("Quanterix" or the "Company"), today announced
- 1y agoAKYAQTRXAkoya Reports Fourth Quarter of 2024 and Full Year Financial ResultsGlobeNewswireMARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year
- 1y agoAKYAQTRXKent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings CallBusiness WireBelieves Proposed Transaction with Akoya Significantly Undervalues Quanterix Encourages Shareholders to Vote Against Transaction to Protect Long-Term Value of their Investment Kent Lake PR LLC ("Kent Lake") is a
- 1y agoAKYAQTRXKent Lake Issues Investor Presentation Detailing Opposition to Quanterix's Proposed Merger with Akoya BiosciencesBusiness WireBelieves Transaction Significantly Undervalues Quanterix Highlights that Quanterix's Board is Essentially Rescuing Akoya at the Direct Expense of Quanterix Shareholders Transaction Would Introduce Unnecessary Risk and
- 1y agoAKYACMBMCSCODOMO+9Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix BoardBusiness WireBelieves Incumbent Board's Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment
- 1y agoAKYAQTRXKent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya BiosciencesBusiness WireBelieves Merger Agreement Significantly Undervalues Quanterix Kent Lake PR LLC ("Kent Lake"), a holder of 5.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX),
- 1y agoAKYAAkoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology PanelsGlobeNewswireRapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE IO Panels The new offerings solidify leadership in spatial biology and broaden reach to
- 1y agoAKYAAkoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing PartnerBusiness WireLong-standing partnership strengthens as both companies target growth in IVD sector Argonaut Manufacturing Services ("Argonaut"), a leading contract development and manufacturing organization serving the biopharma and
- 1y agoAKYAQTRXQuanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein BiomarkersBusiness WireComplementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities
- 1y agoAKYAAkoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment DecisionsGlobeNewswireMARLBOROUGH, Mass. and FRANKFURT, Germany, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company, and NeraCare, a leading developer of laboratory tests for the prognosis
- 1y agoAKYANature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry MilestoneGlobeNewswireMARLBOROUGH, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, announced that Nature Methods, one of the world's leading scientific journals,
- 1y agoONCYAKYACKPTBCTX+1Biotech Advances Drive Cancer Research as Global Rates Continue Upward TrendPR NewswireUSA News Group News Commentary – Despite death rates for some cancers being on the decline, there is a global surge in cancer cases among people...
- 1y agoAKYAAkoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoAKYAAkoya Biosciences Reports Third Quarter 2024 Financial ResultsGlobeNewswireMARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30,
- 2y agoAKYAAkoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO PanelGlobeNewswirePre-orders now available; early access available for select strategic partners for the PhenoCode IO60 panel – The Fastest Ultrahigh-plex Panel for Immuno-Oncology Research Launches the Mouse FFPE IO panel, optimized for
- 2y agoAKYAAkoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024GlobeNewswireMARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of
- 2y agoAKYAAkoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer ImmunotherapyGlobeNewswireConsortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust Akoya's platforms will be used for deep spatial proteomic profiling of
- 2y agoAKYAAkoya Biosciences Announces Scott Mendel as Chairman of the Board of DirectorsGlobeNewswireMARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board,
- 2y agoAKYAAkoya Biosciences, Inc. (AKYA) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoAKYAAkoya Biosciences Reports Second Quarter 2024 Financial ResultsGlobeNewswireMARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30,
- 2y agoAKYAAkoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor ConferencesGlobeNewswireMARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of
- 2y agoAKYAAkoya Biosciences, Inc. (AKYA) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoAKYAAkoya Biosciences Reports First Quarter 2024 Financial ResultsGlobeNewswireMARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31,
- 2y agoAKYAAkoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma PatientsGlobeNewswireMARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for the
- 2y agoAKYAAkoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, MassachusettsGlobeNewswireMARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough,
- 2y agoAKYAAkoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical WorkflowsGlobeNewswireMARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing molecular
- 2y agoAKYAAkoya to Report First Quarter 2024 Financial Results on May 13th, 2024GlobeNewswireMARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of
- 2y agoAKYAAkoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and ScaleGlobeNewswireMARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0
- 2y agoAKYAAkoya Biosciences Names BostonGene as a Qualified CRO Service ProviderBusiness WireBringing End-to-End Spatial Biology Solutions to Life Sciences Researchers for Advanced Spatial Proteomics Analysis BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today
- 2y agoAKYAAkoya Biosciences, Inc. (AKYA) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoAKYAAkoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial OutlookGlobeNewswireQ4 2023 revenue $26.5 million and FY 2023 revenue $96.6 millionGuiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024 MARLBOROUGH, Mass., March 04, 2024 (GLOBE NEWSWIRE) --
- 2y agoAKYAAkoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor ConferenceGlobeNewswireMARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter
- 2y agoAKYAAkoya Biosciences' Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other DiseasesGlobeNewswireMARLBOROUGH, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced that the newly established Queensland Spatial Biology Centre (QSBC),
- 2y agoAKYARIGLAkoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory BoardGlobeNewswireMARLBOROUGH, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the establishment of its Scientific Advisory Board (SAB) to provide
- 2y agoAKYAAkoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine PlatformGlobeNewswireMaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities Development and application of MaxFuse were described in two recent
- 2y agoAKYAAkoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 OutlookGlobeNewswireMARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full
- 2y agoAKYAAkoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics WorkflowGlobeNewswireMARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced that it has entered into a license and distribution agreement with Thermo
- 2y agoAKYAAkoya to Participate at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireMARLBOROUGH, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will be participating in the 42nd Annual J.P. Morgan